CN107922981B - 用于增强在痘病毒中的表达的启动子 - Google Patents

用于增强在痘病毒中的表达的启动子 Download PDF

Info

Publication number
CN107922981B
CN107922981B CN201680042251.3A CN201680042251A CN107922981B CN 107922981 B CN107922981 B CN 107922981B CN 201680042251 A CN201680042251 A CN 201680042251A CN 107922981 B CN107922981 B CN 107922981B
Authority
CN
China
Prior art keywords
ser
pro
ala
leu
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680042251.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN107922981A (zh
Inventor
阿兰·德尔凯尔
李曽基
瑞安·朗特里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bavarian Nordic AS
Original Assignee
Bavarian Nordic AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic AS filed Critical Bavarian Nordic AS
Publication of CN107922981A publication Critical patent/CN107922981A/zh
Application granted granted Critical
Publication of CN107922981B publication Critical patent/CN107922981B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201680042251.3A 2015-07-31 2016-07-28 用于增强在痘病毒中的表达的启动子 Active CN107922981B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562199681P 2015-07-31 2015-07-31
US62/199,681 2015-07-31
PCT/IB2016/001183 WO2017021776A1 (en) 2015-07-31 2016-07-28 Promoters for enhancing expression in poxviruses

Publications (2)

Publication Number Publication Date
CN107922981A CN107922981A (zh) 2018-04-17
CN107922981B true CN107922981B (zh) 2022-02-25

Family

ID=57068152

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680042251.3A Active CN107922981B (zh) 2015-07-31 2016-07-28 用于增强在痘病毒中的表达的启动子

Country Status (15)

Country Link
US (1) US11753652B2 (enExample)
EP (1) EP3329016B1 (enExample)
JP (1) JP6851364B2 (enExample)
KR (1) KR102565284B1 (enExample)
CN (1) CN107922981B (enExample)
AU (1) AU2016303378B2 (enExample)
CA (1) CA2990549A1 (enExample)
DK (1) DK3329016T3 (enExample)
ES (1) ES2901468T3 (enExample)
IL (1) IL256869B (enExample)
MX (1) MX389312B (enExample)
RU (1) RU2753884C2 (enExample)
SG (1) SG10202000447YA (enExample)
WO (1) WO2017021776A1 (enExample)
ZA (1) ZA201800104B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7202362B2 (ja) 2017-08-24 2023-01-11 バヴァリアン・ノルディック・アクティーゼルスカブ 組み換えｍｖａ及び抗体の静脈内投与を用いた、がん治療のための併用療法
MX2020006471A (es) 2017-12-19 2020-09-22 Janssen Sciences Ireland Unlimited Co Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv).
EP3860641A1 (en) 2018-10-05 2021-08-11 Bavarian Nordic A/S Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
BR112021009856A8 (pt) 2018-11-20 2021-09-08 Bavarian Nordic As Terapia para tratamento do câncer com uma administração intratumoral e / ou intravenosa de um mva recombinante que codifica 4-1bbl (cd137l) e / ou cd40l
BR112022009798A2 (pt) 2019-11-20 2022-10-18 Bavarian Nordic As Vírus mva recombinante para administração intratumoral e/ou intravenosa para tratamento de câncer
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
CA3240596A1 (en) 2021-12-23 2023-06-29 Cigdem ATAY LANGBEIN Therapy for modulating immune response with recombinant mva encoding il-12
AU2024208643A1 (en) 2023-01-12 2025-06-26 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670367A (en) * 1991-08-26 1997-09-23 Immuno Aktiengesellschaft Recombinant fowlpox virus
RU2180352C2 (ru) * 1999-11-24 2002-03-10 Государственный научный центр вирусологии и биотехнологии "Вектор" ФРАГМЕНТ ГЕНОМА ВИРУСА ОСПЫ КУР ШТАММА "К", СОДЕРЖАЩИЙ ГЕН ТИМИДИНКИНАЗЫ, РЕКОМБИНАНТНЫЕ ПЛАЗМИДНЫЕ ДНК pTK1FPV И pTK2FPV, СОДЕРЖАЩИЕ ЭТУ ПОСЛЕДОВАТЕЛЬНОСТЬ, И РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pINTFPV1, ОБЛАДАЮЩАЯ СПОСОБНОСТЬЮ ИНТЕГРИРОВАТЬСЯ В ГЕНОМ ВИРУСА ОСПЫ КУР
WO2005038028A1 (en) * 2003-10-15 2005-04-28 Virax Development Pty Ltd Poxvirus vector encoding retrovirus (eg hiv) and cytokine
WO2008106551A2 (en) * 2007-02-28 2008-09-04 The Govt. Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Serv. Brachyury polypeptides and methods for use
CN101775410A (zh) * 2009-01-09 2010-07-14 中国人民解放军军事医学科学院军事兽医研究所 一种鸡痘病毒载体穿梭质粒及其应用
CN102321637A (zh) * 2011-09-09 2012-01-18 中国人民解放军军事医学科学院军事兽医研究所 中国鸡痘病毒282e4弱毒株全基因组序列及其应用
CN102458458A (zh) * 2009-04-17 2012-05-16 全球免疫股份有限公司 组合免疫疗法组合物和方法
WO2014043535A1 (en) * 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766598A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
WO1998004727A1 (en) 1996-07-25 1998-02-05 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
WO2005048957A2 (en) 2003-02-20 2005-06-02 Therion Biologics Corporation Novel insertion sites in pox vectors

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670367A (en) * 1991-08-26 1997-09-23 Immuno Aktiengesellschaft Recombinant fowlpox virus
RU2180352C2 (ru) * 1999-11-24 2002-03-10 Государственный научный центр вирусологии и биотехнологии "Вектор" ФРАГМЕНТ ГЕНОМА ВИРУСА ОСПЫ КУР ШТАММА "К", СОДЕРЖАЩИЙ ГЕН ТИМИДИНКИНАЗЫ, РЕКОМБИНАНТНЫЕ ПЛАЗМИДНЫЕ ДНК pTK1FPV И pTK2FPV, СОДЕРЖАЩИЕ ЭТУ ПОСЛЕДОВАТЕЛЬНОСТЬ, И РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pINTFPV1, ОБЛАДАЮЩАЯ СПОСОБНОСТЬЮ ИНТЕГРИРОВАТЬСЯ В ГЕНОМ ВИРУСА ОСПЫ КУР
WO2005038028A1 (en) * 2003-10-15 2005-04-28 Virax Development Pty Ltd Poxvirus vector encoding retrovirus (eg hiv) and cytokine
WO2008106551A2 (en) * 2007-02-28 2008-09-04 The Govt. Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Serv. Brachyury polypeptides and methods for use
CN101775410A (zh) * 2009-01-09 2010-07-14 中国人民解放军军事医学科学院军事兽医研究所 一种鸡痘病毒载体穿梭质粒及其应用
CN102458458A (zh) * 2009-04-17 2012-05-16 全球免疫股份有限公司 组合免疫疗法组合物和方法
CN102321637A (zh) * 2011-09-09 2012-01-18 中国人民解放军军事医学科学院军事兽医研究所 中国鸡痘病毒282e4弱毒株全基因组序列及其应用
WO2014043535A1 (en) * 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer

Also Published As

Publication number Publication date
MX2018001055A (es) 2018-05-17
RU2753884C2 (ru) 2021-08-24
WO2017021776A1 (en) 2017-02-09
BR112018002172A2 (pt) 2018-09-18
KR20180033498A (ko) 2018-04-03
AU2016303378A1 (en) 2018-01-25
HK1254405A1 (en) 2019-07-19
EP3329016B1 (en) 2021-10-20
ZA201800104B (en) 2022-04-28
JP6851364B2 (ja) 2021-03-31
EP3329016A1 (en) 2018-06-06
RU2018106643A3 (enExample) 2020-01-30
CA2990549A1 (en) 2017-02-09
IL256869B (en) 2022-07-01
NZ738713A (en) 2024-11-29
AU2016303378B2 (en) 2021-12-23
KR102565284B1 (ko) 2023-08-08
RU2018106643A (ru) 2019-08-28
ES2901468T3 (es) 2022-03-22
DK3329016T3 (da) 2022-01-10
IL256869A (en) 2018-03-29
SG10202000447YA (en) 2020-03-30
BR112018002172A8 (pt) 2024-02-15
US11753652B2 (en) 2023-09-12
CN107922981A (zh) 2018-04-17
JP2018521651A (ja) 2018-08-09
US20180216134A1 (en) 2018-08-02
MX389312B (es) 2025-03-20

Similar Documents

Publication Publication Date Title
CN107922981B (zh) 用于增强在痘病毒中的表达的启动子
JP6818797B2 (ja) 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答
AU2009319336B2 (en) Promoters for recombinant viral expression
US9951352B2 (en) Poxvirus expression system
ES2380731T3 (es) Vacunas basadas en el uso de VMA
CN105879060A (zh) 成纤维激活蛋白α为靶点的肿瘤DNA疫苗及病毒载体疫苗
HK1254405B (en) Promoters for enhancing expression in poxviruses
BR112018002172B1 (pt) Promotores para intensificar a expressão em poxvírus
HK40044708A (en) Pr13.5 promoter for robust t-cell and antibody responses
HK1161677A1 (zh) 结合重复免疫的优化早晚期启动子辅助对复制缺陷型重组病毒疫苗抗原的细胞毒t细胞应答

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant